This new specialty Zanextra is already available in Germany, Australia, Ireland, Finland, Denmark, Greece, South Africa and in the Netherlands.
Giovanni Recordati, chairman and CEO of Recordati, said: “The launch of Zanextra in France, the largest market for lercanidipine, is an important event for the growth of our group. We are confident that the excellent therapeutic characteristics of this new specialty and the quality of our French medical representatives, which has been recognized by doctors in France, will ensure the success of Zanextra.”